PMID: 7541548Jan 1, 1995Paper

Profile of doxazosin in patients with benign prostatic hyperplasia

Scandinavian Journal of Urology and Nephrology. Supplementum
R A Janknegt

Abstract

Alpha adrenergic receptors in prostatic smooth muscle play a major role in the development of bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH). As a result, alpha adrenoceptor antagonists have been used increasingly in the treatment of this condition. Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment. In placebo-controlled trials, doxazosin has been shown to improve maximum and mean urine flow rates, reduce urethral resistance and bladder contractility, and improve obstructive and irritative symptoms. These changes develop within a few weeks of starting treatment and are maintained during long-term treatment over periods of years. Doxazosin is also well tolerated; adverse events are generally mild or moderate and do not interfere with treatment. These features combine to make doxazosin an effective, convenient and well-tolerated treatment for the management of patients with BPH.

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.